Stephen F. Betz, Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 3,000 shares at $49.43 ($148K) on 2024-05-10, disclosed to the SEC on 2024-05-14.
Scheduled sale ($148k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CRNX | SELL | 2025-03-21 | $385K | — | Filing → |
| CRNX | SELL | 2024-09-12 | $107K | — | Filing → |
| CRNX | SELL | 2024-08-28 | $160K | — | Filing → |